Phase III trial of BC 819 in patients with bladder cancer that was resistant to initial treatment with BCG.

Trial Profile

Phase III trial of BC 819 in patients with bladder cancer that was resistant to initial treatment with BCG.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs BC 819 (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BCG Refractory
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 15 Nov 2017 According to a BioCancell Therapeutics media release, Patients are being followed for up to 2 years, and the median follow-up at the time of the analysis is approximately 18 months.
    • 15 Nov 2017 According to a BioCancell Therapeutics media release, Full data has been submitted to the 2018 Genitourinary Cancers Symposium Annual meeting.
    • 14 Aug 2017 This trial will be performed under a Special Protocol Assessment provision of the US FDA, as reported in a BioCancell Therapeutics media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top